<DOC>
	<DOCNO>NCT00969553</DOCNO>
	<brief_summary>The primary objective trial identify maximum tolerate dose ( MTD ) BI 6727 Asian cancer patient , provide safety data term drug-related adverse event .</brief_summary>
	<brief_title>Dose Finding Study BI 6727 ( Volasertib ) Patients With Various Solid Cancers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Patients histologically cytologically confirm diagnosis advance solid cancer 2 . Age 18 year old 3 . Written inform consent 4 . Eastern Cooperative Oncology Group ( ECOG ) performance score 2 less Exclusion criterion : 1 . Serious illness concomitant nononcological disease . 2 . Pregnancy breast feed 3 . Active infectious disease 4 . Absolute neutrophil count le 1,500/cubic millimeter 5 . Platelet count le 100,000/cubic millimeter 6 . Bilirubin great 1.5 mg/dL ( &gt; 26 Âµmol/L , SI unit equivalent ) 7 . Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) great 2.5 time upper limit normal 8 . Serum creatinine great 1.5x ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>